11.08.2023 - Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023 Received $5 Million Research and Development Collaboration Milestone Payment from Merck Cash Runway into .
Operator: Good evening, and welcome to Dyadic International s First Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Operator: Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2023 Financial Business Results Conference Call.